Hainan Haiyao Co., Ltd.

000566

CNE0000004W8

HAINAN HAIYAO CO., LTD. is a China-based company principally engaged in the research, development, manufacture and sale of medicines and medical instrument. The Companyâs main products consist of six categories, including cephalosporin series, stomach and intestine medicines, anti-tumor medicines, cochlear implant series, bulk drugs and intermediate series. The Company distributes its products in domestic market and to overseas market, with China as its main market.

Employees

2,108

Sector

Pharmaceuticals

Calendar

2024-10-24 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement and Estimates

More financial data

End-of-day quote Shenzhen S.E. Other stock markets 2024-09-13			5-day change	1st Jan Change
5.430 ^CNY	+9.92%		+61.13%	+20.13%

Sep. 12	Hainan Haiyao Disposing Subsidiary's Idle Assets for 120 Million Yuan; Shares Rise 10%	MT
Sep. 10	Hainan Haiyao Estimates At Least 15 Million Yuan of Asset Losses Due to Makar Typhoon	MT

Hainan Haiyao Disposing Subsidiary's Idle Assets for 120 Million Yuan; Shares Rise 10%	Sep. 12	MT
Hainan Haiyao Estimates At Least 15 Million Yuan of Asset Losses Due to Makar Typhoon	Sep. 10	MT
Hainan Haiyao Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024	Aug. 29	CI
Hainan Haiyao Vice Chair Resigns	Aug. 14	MT
China Shares Rise On Upcoming Economic Data; Hainan Haiyao Soars 10%	Aug. 13	MT
Hainan Haiyao Gets Commercialization Rights for Pharmathen's Schizophrenia Drug; Shares Up 10%	Aug. 13	MT
New Zealand Shares Jump on US Rate Cut Optimism; AFT Pharmaceuticals to Launch Topical Medication in China	Jul. 09	MT
AFT Pharmaceuticals to Launch Skin Infection Cream in China	Jul. 08	MT
AFT Pharmaceuticals Announces an Agreement with Hainan Haiyao Co. Ltd to Distribute Crystaderm® Cream in China	Jul. 08	CI
Hainan Haiyao Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 29	CI
Hainan Haiyao Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 26	CI
Hainan Haiyao’s Antibiotic Passes Generic Evaluation	Jan. 31	MT
Hainan Haiyao's Unit Gets Nod to Become Marketing License Holder of Shuangshen Huoxue Tongluo Granules	Dec. 08	MT
Hainan Haiyao Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-27	CI
China Sanctions Hainan Haiyao, Former Vice Chairman Over Information Disclosure Violations	23-10-05	MT
Hainan Haiyao Co., Ltd.(XSEC:000566) added to S&P Global BMI Index	23-09-18	CI
Hainan Haiyao Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-28	CI
Hainan Haiyao Unit Receives 1.2 Million Yuan Government Subsidy	23-08-21	MT
Hainan Haiyao Co., Ltd. Announces Management Changes	23-06-01	CI
Hainan Haiyao Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-26	CI
Hainan Haiyao Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-10	CI
Hainan Haiyao Unit's Minocycline Hydrochloride Capsules Passes Drug Regulator's Evaluation	23-03-08	MT
Hainan Haiyao Unit Gets Regulatory Nod for Antibacterial Drug	23-01-31	MT
Hainan Haiyao Gets Regulatory Nod for Anti-Skin Disease Drug	23-01-09	MT
Xinxing Cathay International Capital Holdings Limited agreed completed the acquisition of 43% stake in Shanghai Listent Medical Tech Co., Ltd. from Hainan Haiyao Co., Ltd.	23-01-06	CI

Hainan Haiyao Co., Ltd.

Equities

000566

CNE0000004W8

Pharmaceuticals

Latest news about Hainan Haiyao Co., Ltd.

Chart Hainan Haiyao Co., Ltd.

Company Profile

Income Statement and Estimates